Theralase® Granted Canadian Anti-Cancer Patent
Theralase® Granted Canadian Patent for Metal-Glycoprotein Complexes Used to Hunt Cancer Cells and When Laser Light Activated Destroy Them
Toronto, Ontario – November 15, 2018
Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations, used to safely and effectively destroy various cancers is pleased to announce that it has been granted a Canadian patent protecting its unique metal-glycoprotein complexes used to hunt cancer cells and when laser light activated destroy them.
The Canadian patent entitled, “Metal-Glycoprotein Complexes And Their Use As Chemotherapeutic Compounds” is critical in protecting Theralase’s systemic and targeted anti-cancer therapies to allow PDCs and their associated drug formulations to be systemically injected to hunt and destroy cancer cells for various cancer conditions.
Arkady Mandel, M.D., Ph.D., D.Sc., Interim Chief Executive Officer and Chief Scientific Officer, Theralase® stated that, “The granting of this key patent is timely as we embark on the commencement of a Phase II Non-Muscle Invasive Bladder Cancer (“NMIBC”) clinical study and complete the preclinical research for two additional cancer indications; specifically: GlioBlastoma Multiforme (“GBM”), a deadly form of brain cancer and Non-Small Cell Lung Cancer (“NSCLC”). This patent validates the proprietary position of the Company’s anti-cancer technology for the Canadian healthcare market, demonstrating Theralase’s ongoing commitment to the development of a comprehensive intellectual property portfolio, to protect the Company’s future interests, as well as to be attractive to an early stage partner, when the time is right. The latest patent contains significant potential to advance the Company’s anti-cancer Photo Dynamic Therapy (“PDT”) and its associated anti-cancer immune response to additional cancer targets; including: GBM and NSCLC. I am pleased that the patent that protects our advanced PDC formulations and the technology behind it, is in full force in Canada.”
About the Patent
Compositions of the invention include glycoproteins, such as transferrin, and metal-based coordination complexes, which are preferably chemotherapeutic compounds and more preferably tunable PDCs. The compositions are useful as in vivo diagnostic agents, and as therapeutic agents for treating or preventing diseases including those that involve hyperproliferating cells in their etiology, such as cancer, and microbial cells, such as: bacteria, fungi and protozoa.
About Theralase® Technologies Inc.
Theralase® is a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds and their associated drug formulations intended to safely and effectively destroy various cancers.
This news release contains “forward-looking statements” which reflect the current expectations of management of the Corporation’s future growth, results of operations, performance and business prospects and opportunities. Such statements include, but are not limited to, statements regarding Theralase’s proposed development plans with respect to Photo Dynamic Compounds and their drug formulations. Wherever possible, words such as “may”, “would”, “could”, “should”, “will”, “anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate”,”potential for” and similar expressions have been used to identify these forward-looking statements. These statements reflect management’s current beliefs with respect to future events and are based on information currently available to management. Forward-looking statements involve significant risks, uncertainties and assumptions including with respect to the ability of Theralase to: successfully fund and complete a Phase II NMIBC clinical study, successfully fund and complete a Phase Ib GBM clinical study, successfully fund and complete a Phase Ib NSCLC clinical study, secure the requisite regulatory approvals to commence and fund a Phase II NMIBC clinical study, Phase Ib GBM clinical study and/or a Phase Ib NSCLC clinical study and implement its development plans. Many factors could cause the Corporation’s actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements; including, without limitation, those listed in the filings made by the Corporation with the Canadian securities regulatory authorities (which may be viewed at www.sedar.com). Should one or more of these risks or uncertainties materialize or should assumptions underlying the forward looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in the press release are based upon what management currently believes to be reasonable assumptions, the Corporation cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements. The Corporation disclaims any intention or obligation to revise forward-looking statements whether as a result of new information, future developments or otherwise except as required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.
For More Information: